EMBRAER (EMBR3) Main Indicators
Basic Data - EMBR3
| Company | EMBRAER |
| Corporate Name | EMBRAER S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Projeto. desenvolvimento. fabricação. comercialização de aeronaves e sistemas e fornecimento de suporte e serviços de pós-venda. |
| Share | EMBR3 |
| Quote Date | 09/18/2024 |
| Share Type | ON |
| Last Closing | R$ 47.45 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 232.79 M |
| Last Statement | ITR - 06/30/2024 |
| Sector | Bens Industriais |
| Subsector | Material de Transporte |
| Segment | Material Aeronáutico e de Defesa |
| Participation Indexes | GPTW, IBOVESPA, IBRA, IBRX, IBRX50, ICO2, IGC, IGCT, IGNM, INDX, ITAG, IVBX, MLCX |
| Updated 09/19/2024 | |
Relative Prices - EMBR3
| Price/Earnings | 18.38 |
| Price/SBV | 2.21 |
| Price/Net Sales | 1.24 |
| Price/CFO | 8.88 |
| Price/FCF | 12.81 |
| Price/Total Assets | 0.58 |
| Price/EBIT | 16.79 |
| Price/Working Capital | 3.25 |
| Price/NCAV | -1.04 |
| EV/EBIT | 21.94 |
| EV/EBITDA | 13.89 |
| EV/Net Sales | 1.62 |
| EV/CFO | 11.60 |
| EV/FCF | 16.74 |
| EV/Total Assets | 0.76 |
| Company Market Cap | R$ 35.14 B |
| Enterprise Value | R$ 45.91 B |
| Current Financial Statement Date | 06/30/2024 |
| Current Share Price | R$ 47.45 |
| Share Price Date | 09/18/2024 |
| Dividend Yield | 0.00% |
| Updated 09/19/2024 | |
Income Statement - EMBR3
| Net Revenue | R$ 28.32 B |
| Gross Result | R$ 4.91 B |
| EBIT | R$ 2.09 B |
| Depreciation and Amortization | - R$ 1.21 B |
| EBITDA | R$ 3.30 B |
| Net Profit | R$ 1.91 B |
| Net Profit/Share | R$ 2.58 |
| Updated 08/08/2024 | |
| Net Revenue | R$ 7.85 B |
| Gross Result | R$ 1.26 B |
| EBIT | R$ 668.51 M |
| Depreciation and Amortization | - R$ 304.18 M |
| EBITDA | R$ 972.69 M |
| Net Profit | R$ 520.69 M |
| Profit/Share | R$ 0.70 |
| Updated 08/08/2024 | |
Price and Volume Behavior - EMBR3
| Lowest Price 52 weeks | R$ 16.67 |
| Highest Price 52 weeks | R$ 51.93 |
| Variation 2024 | 115.49% |
| Variation 1 year | 164.35% |
| Variation 2 years(total) | 258.11% |
| Variation 2 years(yearly) | 88.75% |
| Variation 3 years(total) | 127.25% |
| Variation 3 years(yearly) | 31.41% |
| Variation 4 years(total) | 610.33% |
| Variation 4 years(yearly) | 63.20% |
| Variation 5 years(total) | 143.33% |
| Variation 5 years(yearly) | 19.44% |
| Average Daily Volume (3 months) | R$ 355.65 M |
| Updated 09/19/2024 | |
Returns and Margins - EMBR3
| Return on Initial Tangible Capital | 7.47% |
| Return on Initial Invested Capital | 6.18% |
| Pre-Tax Return on Initial Tangible Capital | 11.31% |
| Pre-Tax Return on Initial Invested Capital | 9.36% |
| Return on Initial Shareholder´s Equity | 15.79% |
| Return on Initial Asset | 3.70% |
| Gross Margin | 17.32% |
| Net Margin | 6.75% |
| EBIT Margin | 7.39% |
| EBITDA Margin | 11.67% |
| Initial Asset Turnover | 0.55 |
| Financial Leverage | 3.80 |
| Liabilities/Net Worth | 2.80 |
| Net Debt/EBITDA | 3.26 |
| Updated 08/08/2024 | |
Balance Sheet - EMBR3
| Cash and Cash Equivalents | R$ 4.01 B |
| Total Assets | R$ 60.46 B |
| Short-Term Debt | R$ 703.38 M |
| Long-Term Debt | R$ 14.08 B |
| Gross Debt | R$ 14.79 B |
| Net Debt | R$ 10.78 B |
| Shareholder´s Equity | R$ 15.92 B |
| Share Book Value | R$ 21.49 |
| Common Shares | 740,465,000 |
| Preferred Shares | 0 |
| Total | 740,465,000 |
| Common Shares in Treasury | 5,832,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 5,832,000 |
| Common Shares (Except Treasury) | 734,633,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 734,633,000 |
| Updated 08/08/2024 | |
Cash Flow - EMBR3
| Operating Cash Flow | R$ 3.96 B |
| Cash Flow from Investments | - R$ 2.85 B |
| Financing Cash Flow | - R$ 4.27 B |
| Increase (Reduction) in Cash and Equivalents | - R$ 2.52 B |
| Updated 08/08/2024 | |
| Operating Cash Flow | - R$ 151.48 M |
| Cash Flow from Investments | - R$ 757.87 M |
| Financing Cash Flow | - R$ 71.76 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 576.60 M |
| Updated 08/08/2024 | |
Experimental - EMBR3
| CAPEX 3 months | - R$ 298.88 M |
| Free Cash Flow 3 months | - R$ 450.36 M |
| CAPEX 12 months | - R$ 1.21 B |
| Free Cash Flow 12 months | R$ 2.74 B |
| Updated 08/08/2024 | |